Regular Article
Inhibitory Effect of Full-Length Human Endostatin on in Vitro Angiogenesis

https://doi.org/10.1006/bbrc.1999.1342Get rights and content

Abstract

Endostatin, a C-terminal product of collagen XVIII, is a very powerful angiogenesis inhibitor. In vivo experiments in mice indicate that endostatin dramatically reduces tumor mass without causing the onset of any resistance to the treatment. Recently, a 12-aa shorter human endostatin has been purified from plasma, but is ineffective in in vitro angiogenesis assays. Here we report that the full-length human recombinant endostatin has a potent inhibitory activity in in vitro angiogenesis assays. Two powerful angiogenic factors were used to stimulate endothelial cells: FGF-2 and VEGF-165. Endostatin prevented cell growth both in the basal condition and after stimulation with FGF-2 or VEGF-165. Migration of microvascular endothelial cells toward FGF-2 or VEGF-165 was impaired, both when cells were pretreated with the inhibitor and when endostatin was added together with the growth factors. Furthermore, experiments of inhibition of proliferation performed on nonmicroendothelial cells showed that endostatin was ineffective. This study indicates that human endostatin is a potent angiogenesis inhibitor and suggests its use in human anticancer therapy.

References (29)

  • J. Folkman et al.

    J. Biol. Chem.

    (1992)
  • D. Hanahan et al.

    Cell

    (1996)
  • N. Ferrara et al.

    Biochem. Biophys. Res. Commun.

    (1989)
  • K. Thomas

    J. Biol. Chem.

    (1996)
  • L. Standker et al.

    FEBS Lett.

    (1997)
  • P. Chomczynski et al.

    Anal. Biochem.

    (1987)
  • J. Folkman

    Nature Medicine

    (1995)
  • W. Risau

    Nature

    (1997)
  • J. Folkman

    N. Engl. J. Med.

    (1995)
  • D.R. Senger et al.

    Science

    (1983)
  • D. Gospodarowicz et al.

    Proc. Natl. Acad Sci. USA

    (1989)
  • T. Mustonen et al.

    J. Cell Biol.

    (1995)
  • N. Ferrara et al.

    Endocr. Rev.

    (1997)
  • A. Bickfalvi et al.

    Endocr. Rev.

    (1997)
  • Cited by (93)

    • Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications

      2015, Biochimica et Biophysica Acta - General Subjects
      Citation Excerpt :

      Both endogenously produced endostatin and Endostar, recombinant human endostatin, can inhibit angiogenesis in vivo [156]. In mouse models, endostatin has been shown to suppress and even completely inhibit the tumor mass growth rate though inhibition of angiogenesis [163,164]. Although not extensively studied, the results of in vivo experiments support endostatin's anti-lymphangiogenic role based on its inhibition of bFGF-induced lymphangiogenesis [165].

    • Angiogenesis in cutaneous disease: Part I

      2009, Journal of the American Academy of Dermatology
    • The endothelium in lung fibrosis: a core signaling hub in disease pathogenesis?

      2023, American Journal of Physiology - Cell Physiology
    View all citing articles on Scopus

    Abbreviations used: CVEC, capillary venular endothelial cells; FGF-2, fibroblast growth factor 2; VEGF/VPF, vascular endothelial growth factor/vascular permeability factor

    1

    To whom correspondence should be addressed. Fax: 39-055-4222725. E-mail: [email protected].

    View full text